Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P79.01 - TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezolizumab with Chemoradiation (AFT-16)
00:00 - 00:00 | Presenter: Woo Yul Byun
- Abstract
Loading... -
+
P79.02 - Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC
00:00 - 00:00 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
P79.03 - A Phase 3 Study of the PD-1 Inhibitor Retifanlimab (INCMGA00012) Plus Platinum-Based Chemotherapy in 1L mNSCLC: POD1UM-304
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P79.04 - A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis.
00:00 - 00:00 | Presenter: Dwight H Owen
- Abstract
Loading... -
+
P79.05 - Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Caroline Huynh
- Abstract
Loading... -
+
P79.06 - CHIO3: ChEmotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer (AFT-46)
00:00 - 00:00 | Presenter: Linda W Martin
- Abstract
Loading... -
+
P79.07 - Comparative Efficacy and Safety of PD-(L)1 Inhibitors Combined with 1st-Line Chemotherapy for Advanced NSCLC: A Meta-Analysis
00:00 - 00:00 | Presenter: Alessandro Di Federico
- Abstract
Loading... -
+
P79.08 - Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P79.09 - Neoadjuvant Combination Sintilimab plus Chemotherapy in Patients with Resectable Stage IIIA Non-Small Cell Lung Cancer.
00:00 - 00:00 | Presenter: Kewei Ma
- Abstract
Loading...
-
+
P80 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy/ Immunotherapy Plus Targeted Therapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P80.01 - A Multicenter, Randomized, Phase 3 Trial of Penpulimab in Combination With Anlotinib or Chemotherapy as First-Line Treatment in Advanced NSCLC
00:00 - 00:00 | Presenter: Baohui Han
- Abstract
Loading...
-
+
P81 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy/Immune Checkpoint Inhibitor Single Agent
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P81.01 - Efficacy and Safety of Camrelizumab in Patients with Advanced Lung Cancer: A Multicentre, Prospective, Observational Study.
00:00 - 00:00 | Presenter: Yong Qian Shu
- Abstract
Loading... -
+
P81.02 - Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
00:00 - 00:00 | Presenter: Shikang Zhao
- Abstract
Loading...
-
+
P82 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Radiotherapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P82.01 - Tumor Treating Fields (150 kHz) Concurrent with Immune Check Point Inhibitors for Stage 4 Non-Small Cell Lung Cancer (NSCLC) in Phase 3 LUNAR Study
00:00 - 00:00 | Presenter: Ticiana Leal
- Abstract
Loading... -
+
P82.02 - Stereotactic Ablative Radiotherapy with Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a phase 2 study
00:00 - 00:00 | Presenter: Juliana Rodrigues Beal
- Abstract
Loading... -
+
P82.03 - Immunotherapy in Combination with Hypofractionated Radiotherapy for Lung Cancer: A Real-World Experience
00:00 - 00:00 | Presenter: Naveen Mummudi
- Abstract
Loading... -
+
P82.04 - Adaptive Radiation Therapy with Consolidation Sintilimab in Stage III NSCLC: Challenges in Recruiting Patients for Adjuvant Immunotherapy
00:00 - 00:00 | Presenter: Yinnan Meng
- Abstract
Loading...
-
+
P83 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Targeted Therapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P83.01 - Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC
00:00 - 00:00 | Presenter: Shengxiang Ren
- Abstract
Loading... -
+
P83.02 - Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study
00:00 - 00:00 | Presenter: Suresh S. Ramalingam
- Abstract
Loading... -
+
P83.03 - Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation
00:00 - 00:00 | Presenter: Guanghui Gao
- Abstract
Loading... -
+
P83.04 - Efficacy and Safety of Combining Programmed Cell Death-1 Inhibitor and Anti-Angiogenic Agent as Subsequent Therapy for Advanced NSCLC
00:00 - 00:00 | Presenter: Ziyi Xu
- Abstract
Loading...
-
+
P84 - Targeted Therapy - Clinically Focused - ALK
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P84.01 - The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients.
00:00 - 00:00 | Presenter: Laura Mezquita
- Abstract
Loading... -
+
P84.02 - A Phase II Trial of Alectinib-Refractory Non-Small-Cell Lung Cancer with EML4-ALK Fusion Genes; Okayama Lung Cancer Study Group 1405
00:00 - 00:00 | Presenter: Toshihide Yokoyama
- Abstract
Loading... -
+
P84.03 - GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients
00:00 - 00:00 | Presenter: Nir Peled
- Abstract
Loading... -
+
P84.04 - HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis
00:00 - 00:00 | Presenter: Fang Wu
- Abstract
Loading... -
+
P84.05 - Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial
00:00 - 00:00 | Presenter: Byoung Chul Cho
- Abstract
Loading... -
+
P84.06 - Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study
00:00 - 00:00 | Presenter: Alexis Cortot
- Abstract
Loading... -
+
P84.07 - Distribution and Therapeutic Outcomes of Intergenic Sequence-ALK Fusion and Coexisting ALK Fusions in Lung Adenocarcinoma Patients
00:00 - 00:00 | Presenter: Meijuan Huang
- Abstract
Loading... -
+
P84.08 - First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer: A Network Meta-Analysis
00:00 - 00:00 | Presenter: Huamao M Lin
- Abstract
Loading... -
+
P84.09 - Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC
00:00 - 00:00 | Presenter: Ross Soo
- Abstract
Loading... -
+
P84.10 - The Impact of 3rd-Line ALK Inhibitors in ALK Positive NSCLC in Real-World Data
00:00 - 00:00 | Presenter: Mor Moskovitz
- Abstract
Loading... -
+
P84.11 - Real-World Brigatinib Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in the United States
00:00 - 00:00 | Presenter: Huamao M Lin
- Abstract
Loading... -
+
P84.12 - Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor
00:00 - 00:00 | Presenter: Camila Bragança Xavier
- Abstract
Loading... -
+
P84.13 - Organoid Used as Preclinical Modal in ALK Inhibitor Selection: Report of a Case Harbouring LRRTM4–ALK Fusion
00:00 - 00:00 | Presenter: Ziqi Jia
- Abstract
Loading... -
+
P84.14 - Identification of Mechanisms of Resistance to ALK Inhibitors. Next-Generation Sequencing-Based Liquid Biopsy Profiling.
00:00 - 00:00 | Presenter: Atocha Romero
- Abstract
Loading... -
+
P84.15 - Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China
00:00 - 00:00 | Presenter: Xue Yang
- Abstract
Loading... -
+
P84.16 - Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Yago Garitaonaindía
- Abstract
Loading... -
+
P84.17 - Impacts of Different EML4-ALK Variants on the Efficacy of ALK Inhibitors in ALK Positive NSCLC——A Real-World Study in China.
00:00 - 00:00 | Presenter: Zihua Zou
- Abstract
Loading... -
+
P84.18 - Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
00:00 - 00:00 | Presenter: Zhiwei Xiao
- Abstract
Loading... -
+
P84.19 - A Review of Clinical Outcomes of Irish Patients With ALK Rearranged NSCLC
00:00 - 00:00 | Presenter: Hazel O'Sullivan
- Abstract
Loading... -
+
P84.20 - VATS Right Upper Lobectomy for Advanced Non-Small Cell Lung Cancer After ALK-Tyrosine Kinase Inhibitor Administration.
00:00 - 00:00 | Presenter: Kozo Yamamoto
- Abstract
Loading... -
+
P84.21 - Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient
00:00 - 00:00 | Presenter: Flavia Amaral Duarte
- Abstract
Loading... -
+
P84.22 - Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
00:00 - 00:00 | Presenter: Diego Kaen
- Abstract
Loading... -
+
P84.23 - The Safety and Toxicities of ALK -TKIs in ALK-Positive NSCLC: A Systematic Review and Pool Analysis
00:00 - 00:00 | Presenter: Kewei Ma
- Abstract
Loading...
-
+
P85 - Targeted Therapy - Clinically Focused - MET
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P85.01 - Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC
00:00 - 00:00 | Presenter: Julien Mazieres
- Abstract
Loading... -
+
P85.02 - NGS could not Replace FISH Regarding to MET Amplification as an Optimal Biomarker
00:00 - 00:00 | Presenter: lunxi Peng
- Abstract
Loading... -
+
P85.03 - PD-L1 Expression and Efficacy of Immunotherapy in Japanese Patients with NSCLC Harboring MET Exon 14 Skipping Mutation.
00:00 - 00:00 | Presenter: Yasuhiro Kato
- Abstract
Loading... -
+
P85.04 - Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis
00:00 - 00:00 | Presenter: Ji-Youn Han
- Abstract
Loading... -
+
P85.05 - MET Exon 14 Skipping Mutation Positive Non-Small Cell Lung Cancer: A Population-Based Cohort
00:00 - 00:00 | Presenter: Selina K Wong
- Abstract
Loading... -
+
P85.06 - Clinical and Genomic Features of Middle Intensity cMET Stain of Chinese Lung Cancer Patients
00:00 - 00:00 | Presenter: Xiaorong Dong
- Abstract
Loading... -
+
P85.07 - Neutrophils Counts Deregulated by C-met TKIs and the Variation Predicts Treatment Response in NSCLC
00:00 - 00:00 | Presenter: Xiao-Rong Yang
- Abstract
Loading...
-
+
P86 - Targeted Therapy - Clinically Focused - New Target
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P86.01 - Phase 1 Study of the AXL Inhibitor DS-1205 in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC
00:00 - 00:00 | Presenter: James Chih-Hsin Yang
- Abstract
Loading... -
+
P86.02 - Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study
00:00 - 00:00 | Presenter: Yan Wang
- Abstract
Loading... -
+
P86.03 - A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations
00:00 - 00:00 | Presenter: Hussein Sweiti
- Abstract
Loading... -
+
P86.04 - The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Fen Wang
- Abstract
Loading... -
+
P86.05 - In Vitro Validation Study for HER2 Mutations Identified in Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
00:00 - 00:00 | Presenter: Akira Hamada
- Abstract
Loading... -
+
P86.06 - A Phase I Study of Anlotinib Combined with Platinum-Pemetrexed in Untreated Non-Squamous Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Meijuan Huang
- Abstract
Loading... -
+
P86.07 - CDK12 Mutated Extensive Stage Small Cell Lung Cancer Showed an Exceptional Response to Olaparib and Paclitaxel
00:00 - 00:00 | Presenter: Jin Young Hwang
- Abstract
Loading... -
+
P86.08 - Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
00:00 - 00:00 | Presenter: Alison M Schram
- Abstract
Loading... -
+
P86.09 - A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC
00:00 - 00:00 | Presenter: Jianping Xiong
- Abstract
Loading... -
+
P86.10 - Real-World Efficacy and Safety of Anlotinib with and without Immunotherapy in Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Qi Xiong
- Abstract
Loading... -
+
P86.11 - A Real-World Feasibility Study of Patients with Solid Tumors Harboring NRG1 Gene Fusions: NSCLC Subset Analysis
00:00 - 00:00 | Presenter: Ajeet Gajra
- Abstract
Loading... -
+
P86.12 - Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Nahor Haddish-Berhane
- Abstract
Loading... -
+
P86.13 - Anlotinib is Active for the Patients Failed from the Prior Bevacizumab Treatment: Anti-Angiogenic Therapy might be Cross-Line Used
00:00 - 00:00 | Presenter: Jiang Zhu
- Abstract
Loading... -
+
P86.14 - Next-Generation Sequencing Guided the Gene Mutations Associated with mTOR-Inhibitors in Chinese Lung Cancer Patients
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P86.15 - Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan
00:00 - 00:00 | Presenter: Gee-Chen Chang
- Abstract
Loading... -
+
P86.16 - Rationale of a Phase II Trial of Nivolumab Combined with Anlotinib in Advanced NSCLC Previously Treated with Immunotherapy
00:00 - 00:00 | Presenter: Baohui Han
- Abstract
Loading... -
+
P86.17 - Continuous Administration of Low-Dose Apatinib Combined With WBRT for Non-Small Cell Lung Cancer With Symptomatic Brain Metastases
00:00 - 00:00 | Presenter: Yu-ming Jia
- Abstract
Loading... -
+
P86.18 - Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.
00:00 - 00:00 | Presenter: Juan Bautista Blaquier
- Abstract
Loading... -
+
P86.19 - Anlotinib in Advanced Lung Squamous Cell Carcinoma: A Real World Study
00:00 - 00:00 | Presenter: shujie Song
- Abstract
Loading... -
+
P86.20 - The Prevalence of NTRK1 Fusion in a Chinese Lung Cancer Cohort
00:00 - 00:00 | Presenter: Zhifang Liu
- Abstract
Loading... -
+
P86.21 - Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC
00:00 - 00:00 | Presenter: Shuchen Chen
- Abstract
Loading... -
+
P86.22 - Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study
00:00 - 00:00 | Presenter: Yong Fang
- Abstract
Loading... -
+
P86.23 - Clinical Efficacy Analysis of Apatinib as a Second-Or Further-Line Treatment in Patients With Advanced NSCLC
00:00 - 00:00 | Presenter: Kewei Ma
- Abstract
Loading...
-
+
P87 - Targeted Therapy - Clinically Focused - RET
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P87.01 - Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)
00:00 - 00:00 | Presenter: Nir Peled
- Abstract
Loading... -
+
P87.02 - AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC
00:00 - 00:00 | Presenter: Benjamin Besse
- Abstract
Loading... -
+
P87.03 - Characteristics and Outcomes of RET-Rearranged Non-Small Cell Lung Cancer from China: A Retrospective Study of Real-World
00:00 - 00:00 | Presenter: mina Zhang
- Abstract
Loading... -
+
P87.04 - Chemotherapy and Immunotherapy Outcomes of RET-Rearranged Lung Cancers: A Case Series
00:00 - 00:00 | Presenter: Estelamari Rodriguez
- Abstract
Loading... -
+
P87.05 - RET-Rearranged Squamous Cell Carcinoma of the Lung Responding to First-Line Immunotherapy plus Chemotherapy
00:00 - 00:00 | Presenter: qing-yun Gao
- Abstract
Loading...
-
+
P88 - Targeted Therapy - Clinically Focused - ROS1
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P88.01 - Comprehensive Profiling of ROS1 Fusions in Chinese Non-Small Cell Lung Cancer Patients
00:00 - 00:00 | Presenter: Hanlin Xu
- Abstract
Loading... -
+
P88.02 - SDC4-ROS1 Fusion as a Mechanism of Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Chun-wei Xu
- Abstract
Loading... -
+
P88.03 - Asymptomatic COVID-19 in a ROS1 positive Non Small Cell Lung Cancer.
00:00 - 00:00 | Presenter: Ananda Datta
- Abstract
Loading... -
+
P88.04 - Successful Low-Dose Treatment for Patients with ROS1-Rearranged NSCLC who Developed Crizotinib-Related Heart Failure.
00:00 - 00:00 | Presenter: Takahiko Hashimoto
- Abstract
Loading... -
+
P88.05 - A Recommended one-step Targeted Sequencing Technology for Identification of a Dual CD74-ROS1 in NSCLC
00:00 - 00:00 | Presenter: Quan Lin
- Abstract
Loading...